During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Bristol-Myers Squibb recently reported a strong earnings quarter. **The company raised its full-year revenue guidance by $700 million**. This update reflects robust sales growth from key therapies and ...